Oncorus to Participate in Fireside Chats at Upcoming Piper Sandler Annual Healthcare Conference and Evercore ISI HealthCONx ...
November 24 2020 - 8:00AM
Oncorus, Inc. (Nasdaq:ONCR), a viral immunotherapies company
focused on driving innovation to transform outcomes for cancer
patients, announced today that Theodore (Ted) A. Asbhurn, M.D.,
Ph.D., President and Chief Executive Officer, will participate in
fireside chats at two upcoming investor conferences.
32nd Annual
Piper Sandler Annual Virtual
Healthcare Conference Dates: December 1 - December
3, 2020Webcast: The pre-recorded fireside chat is now available in
the Investors & Media section of Oncorus’ website at
https://investors.oncorus.com/events-and-presentations. The
presentation will be archived on the company’s site for 90
days.
3rd
Annual Evercore ISI
HealthCONx Conference Date:
December 3, 2000Time: 9:40 a.m. ETWebcast: A live webcast of the
presentation will be available in the Investors & Media section
of Oncorus’ website at
https://investors.oncorus.com/events-and-presentations. A replay of
the presentation will be archived on the company’s site.
About Oncorus
At Oncorus, we are focused on driving innovation to deliver
next-generation viral immunotherapies to transform outcomes for
cancer patients. We are advancing a portfolio of intratumorally and
intravenously administered viral immunotherapies for multiple
indications with significant unmet needs based on our oncolytic
Herpes Simplex Virus (oHSV) Platform and Synthetic Virus Platform.
Designed to deliver next-generation viral immunotherapy impact, our
oHSV platform improves upon key characteristics of this therapeutic
class to enhance potency without sacrificing safety, including
greater capacity to encode transgenes to drive systemic
immunostimulatory activity, retention of full replication
competency to enable high tumor-killing potency, and orthogonal
safety strategies to restrict viral activity in tumor cells. Our
lead oHSV program, ONCR-177, is designed to be directly
administered into a tumor, resulting in high local concentrations
of the therapeutic agent, as well as low systemic exposure to the
therapy, which we believe could potentially limit systemic
toxicities. Please visit www.oncorus.com to learn more.
Investor Contact: |
Media
Contact: |
Alan Lada |
Liz Melone |
Solebury Trout |
liz.melone@oncorus.com |
617-221-8006 |
|
alada@soleburytrout.com |
|
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From May 2024 to Jun 2024
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jun 2023 to Jun 2024